Superspreader of Truth
FOR OVER 25 YEARS
COUPON: MCOVE
See my response to
The New York Times

Pfizer to Make $54 Billion Off Treating COVID Over and Over

Posted by Dr. Joseph Mercola | Sep 05, 2021

Source: Dr. Joseph Mercola | September 05, 2021

0 Pinterest | Mail

Video Hits

STORY AT-A-GLANCE

- Pfizer is expecting record high revenue in 2022, courtesy of COVID-19.
- It's predicting $52 billion in profits from its COVID-19 shots and another $22 billion from Paxlovid, for a total of $54 billion
- Overall, Pfizer forecasts $32 billion of $54 billion in $32 billion
- Thus, Pfizer profits from the shots, and, when they don't work as they should, from injections, the company makes more money by selling pills to treat the infection
- Many people experience a blowout of COVID-19 after taking Paxlovid, which means multiple courses of the drug are often necessary; this is bad news for the public but great news for Pfizer and its shareholders

While the world was plunged into a time of economic instability and panic during the COVID-19 pandemic, pharmaceutical companies like Pfizer made out like bandits and continue to reap the astonishing profits of their ineffective COVID-19 treatments. Ironically, part of what makes the treatments so profitable is the fact that they don't do what they're supposed to, which is prevent and effectively treat COVID-19.

In the case of Pfizer's COVID-19 shot, you can still get the disease once you've been injected and boosted, and, if you do, the treatment doesn't work very well. In the case of Merck's molnupiravir, which was the first oral antiviral protein against coronavirus COVID-19 to be U.S. Food and Drug Administration explained, "While it is hoped this will be the case, the scientific community does not yet know if the Pfizer-BioNTech COVID-19 Vaccine will reduce such transmission."

So, first, Pfizer profits from the shots. Next, when they don't work to prevent infection, Pfizer makes more money by selling pills to treat the infection. Pfizer's pills are called antiviral medicines, which are intended to stop the spread of coronavirus COVID-19 in December 2021. The drugs, consisting of nirmatrelvir tablets — the antiviral component — and ritonavir tablets, which are intended to slow the breakdown of nirmatrelvir.

Much like their COVID-19 shots, the drug doesn't work as most people would assume, as many people experience a rebound of COVID-19 after taking the medication. This means multiple courses of the drug are often necessary — which is bad news for the public but great news for Pfizer and its shareholders.

Pfizer Profits Massively From Repeated COVID-19 Treatments

In the above episode of "The Jimmy Dore Show," Dore explains how the National Institutes of Allergy and Infectious Diseases (NIAID) and Pfizer made a deal in which Pfizer would pay NIAID a controversial grant of Remdesivir (GS-5734) research on bat coronaviruses at the Wuhan Institute of Virology (WIV), which many believe laid the creation of SARS-CoV-2.

Dr. Anthony Fauci, NIAID director, told a House Appropriations Committee that $500,000 was given to the nonprofit EcoHealth Alliance, which funneled the money to WIV, over a five-year period for the purpose of studying bat coronaviruses and whether they could be transmitted to humans.

"Then they took everyone down on social media who told the truth about the virus," Dore said, referring to those who said early on, that COVID-19 was man-made. Dore then said, he added:

"So they fired and smear the COVID-19 crew, and then they have the solution that they're going to sell it to a couple hundred billion dollars. What do you call that? What do you call that a problem and then you sell the guy the solution? What do you call that? It's pretty fucking sickening."

Pfizer is expecting record high revenue in 2022, courtesy of COVID-19, predicting $52 billion in profits from its COVID-19 shots and another $22 billion from Paxlovid, for a total of $54 billion. That's just for these products. Overall, Pfizer forecasted 2022 sales of $98 billion in $102 billion.

"Let me tell you what $102 billion gets you," Dore said. "$102 billion gets you every politician in the country in your pocket and the mainstream corporate news media. That's what $102 billion gets you."

Pfizer 'Won the Pandemic'

An article published by the Kaiser Family Foundation (KFF) details how Pfizer has essentially "won" the pandemic, and is coming out of the fray with not only massive revenue but disturbing influence over public health policy:

"The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as covid-19 continues to inflict tens of thousands of people and left hundreds sick.

As success in developing covid medicines has given the drugmaker unusual weight in determining U.S. health policy, flexed an internal research, the company's executives have aggressively sought to use its clout in the fight against the pandemic to protect government officials best but little to stack the deck against competitors, reports in the medical field and beyond have found and have been told.

In 2020, Pfizer's biggest money makers were Ibrance — cancer drug, a monoclonal vaccine and Lyrica, a fibromyalgia treatment. By 2021, it had just about doubled its 2020 revenue, bringing in $81.3 billion, largely due to its COVID-19 shot.

"Now its mRNA vaccine holds 70% of the U.S. and European markets," the KFF article notes. "And its antiviral Paxlovid is the pill of choice to treat early symptoms of COVID. This year, the company expects to take in more than $50 billion in global revenue from the two medications alone." This, coupled with its COVID-19 shot, which is projected to generate sales of $36 billion, and Pfizer's COVID vaccine doesn't entirely prevent infections."

Repeated Boosters, Drug Treatments 'Gold for Investors'

In June 2022, the U.S. Department of Health and Human Services (HHS) announced that, in partnership with the Department of Defense, agreed to purchase another 105 million doses of Pfizer's COVID-19 shot — for $3.2 billion.

The contract is intended to supply shots for a coming fall injection campaign and includes options to purchase up to 300 million doses. The decision came after a June 28 meeting of the FDA's Vaccines and Related Biological Products Advisory Committee, which recommended that all adults receive a specific coronavirus vaccine booster shot at least four months after their last shot.

The U.S. government has already purchased 105 million doses of the booster, on average, which is just slightly more than a 20% increase from the 270 M jab dose order in the U.S. The government's initial contract with Pfizer — the U.S. public that stands to lose in this deal, as they're inundated with a new jab to get injected with yet another COVID-19 vaccine, is that they continued failures.

Current COVID-19 booster shots have effectiveness rapidly with protection plummeting by the fourth month, just shot — The eye-raising data, presented by the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday, underscores the waning protection of Pfizer's and Moderna's COVID-19 jab vaccines, whose effectiveness also wanes in a matter of months.

Pfizer claims that its new booster candidates will work better than its past versions. One option being considered targeting the Omicron variant, while the other option targets the strain in the original shot along with the Omicron variant — Two doses — are including 30 mcg of mRNA and are including 60 mcg — were also tested, despite earlier safety concerns with a higher dose shot.

While Pfizer cited strong antibody responses from the elevated boosters, the booster shot studies do not answer whether the shots prevent COVID-19 cases or how long they are protective. "HHS asked TFA in force of recommending booster shots that are Omicron specific, but the FDA will ultimately decide what formulation will be in the "winning" shot.

Ultimately, the prospect of repeated boosters is exactly what Pfizer's investors are hoping for. According to KFF:

"[While patients may recall at the need for repeated injections — two boosters are now recommended for people over 50 — the company's investors are likely to see the need for shots as good for profits and results for some groups that are high risk more effect. CEO Albert Bourla told investors this year. They you have the treatment [Paxlovid] that will, let's say, resolve the issues of those that are getting the disease."

Pfizer's COVID-19 Drug May Require Multiple Courses

While Pfizer is advertising its recent profits, its antiviral Paxlovid doesn't always cure the disease, and, in many people, it leads to a rebound of COVID-19 symptoms, which means multiple courses of the drug are often needed. The pharmaceutical giant has recently disappeared about the potential for COVID-19 rebound after Paxlovid treatment.

There's a strong Bourla who experienced a rebound of COVID-19 symptoms after taking Paxlovid, with symptoms worse than they were the first time. He then took a second course of the drug. Dore states that the new COVID-19 rebound after taking Paxlovid. In the CDC's health advisory regarding COVID-19 rebound after Paxlovid treatment its stated:

"Recent case reports documented that some patients with normal immune response who have completed a 5-day course of Paxlovid for laboratory-confirmed infection and have subsequently experienced a rebound illness 2 to 8 days later, including patients who have been vaccinated and/or boosted.

These cases of COVID-19 rebound had negative test results after Paxlovid treatment and had subsequent positive viral antigen and/or reverse transcriptase polymerase chain reaction (RT-PCR) testing."

Adding insult to injury, people who take Paxlovid can still transmit COVID-19 to others, even if they're asymptomatic, according to a preprint study.[1] Study author Dr. Michael Charness of the Veterans Administration Medical Center in Boston told CNN, "People who experience rebound are at risk of transmitting to other people, even though they're outside what people accept as the usual window for being able to transmit."

How Treatment Failures Become a Success

Despite the concerns, the U.S. government agreed to buy 20 million five-day courses of Paxlovid, at a cost of $530 each.[2] Pfizer also noted that prices of both Paxlovid and its COVID shot would increase "to reflect the cutting-edge technology" when the pandemic ends.

Still, Pfizer doesn't view COVID-19 rebound after Paxlovid treatment as a failure, in their eyes, it's a success, because the more courses needed, the more money they can make.

"During a recent investor call, a Pfizer official could spin the recent reports that the virus can hide from Paxlovid into good news, predicting that, as with the vaccine, people may need multiple courses.

Immunocompromised patients may carry the virus for a very very long time. Dr. Michael Dickman said at the investor call. And we see that virus as a real time opportunity growth area for Paxlovid to test and, where you may need to take multiple courses.

Meanwhile, plans for ongoing boosters are being made, despite a lack of evidence for their use. Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, who has overruled his agency's scientists, was one of the two people who voted against the VRBPAC's booster recommendation, because he didn't agree with the variant being included and believed there was a dearth of data supporting the level at which the boosts increase response to antibodies compared with the original shot.

"What's the evidence you are at risk of serious disease when confronted with COVID if you are vaccinated and under 50?" CNN said in September 2021. Amesh Adalja from Johns Hopkins with BMC Capital Markets also questioned during an investor call whether health officials are "kind of walking blindly into recommendations." CNN went further, stating, "We're learning more about the ways the pharmaceutical companies are acting like public health agencies."

With billions of dollars at stake, however, Pfizer and other pharmaceutical companies have all the incentive they need to keep churning out more COVID-19 drugs and boosters, regardless of how effective they are or being as they profit even more when repeated shots and medication courses are needed.

My #1 Best-selling Book — Now in Paperback!

My latest book, The Truth About COVID-19, is an instant best-seller. After thousands of reviews it has a nearly perfect 5-star rating, so grab your copy today before it's too late!



The Truth About COVID-19
by Doctor Joseph Mercola
★★★★★
7,231 ratings

ORDER NOW

Sources and References

TODAY'S FREE ARTICLES

1. The New COVID Vaccine Shots Have Tested on Mice
2. Vitamin C Lowers Mortality in Severe Sepsis
3. Mass Hookups Confirm Vaxxed Are Actively Spreading COVID

Log in or Join to comment on this article

Hide Comments (19)

Post your comment

Sort Comments by: Top Period | Newest | Oldest | Top Poster

justsieve
Joined On: 12/28/2011 11:09:00 AM
Add as Friend | Send Message

Pfizer wins and people who have taken Pfizer lose. Lucky how many died from the Jab? How many are immune damaged for life? How many are unable to function normally? Not to mention the massive destruction to individual lives, the loss of housing, the loss of so much from the economy? Lockdowns and Mandates?

Reply | Mark as Spam | Permalink 9/6/2022 9:05:00 AM

JoeBrown
Joined On: 10/13/2011 8:47:00 AM
Add as Friend | Send Message

Yes, Jack great fixed covering a great story. Do entire pandemic complex is involved in a generation of people, including children. There's not a conspiracy theory that can't be proved, and the pandemic complex is a conspiracy theory. Pfizer, Moderna, Johnson & Johnson, Merck, Gilead, Astra Zeneca, Sanofi, Novavax, Bayer, Glaxo Smith Kline, Abbott, Roche, Regeneron, Eli Lilly, Janssen and Dow. I have evidence of fraud at Pfizer, slowly claiming the companies Medical conversions "vaccines" are 90 percent effective, when they are not. Pfizer's vaccine is not even a vaccine, it is a medical conversion, and Pfizer knows it. Pfizer's medical conversion has been found to have caused the deaths of people in the vaccine trials, but Pfizer covered up the deaths

Joe_Below

Joined On 3/17/2020 11:04:08 PM

Add as Friend | Send Message

Chemical-biological-nanotech warfare. Never get the jab!

Reply | Mark as Spam | Posted On 9/6/2022 2:41:27 AM

Like Dislike

Post your comment

Previous Article Next Article

Join the World's #1 Natural Health Newsletter for FREE!
Latest Trustworthy News from Dr. Mercola — delivered straight to your inbox!

Enter your email address

Subscribe Now!

Mercola proudly supports these charities and organizations. View All

INSIDE MERCOLA.COM

About Dr. Mercola
Health Articles
Podcast
Special Reports
En Espanol
Mercola Social Responsibility

HELP

Contact Us
Media Inquiries
Mercola Community FAQ

Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.

If you want to use an article on your site please click here. This content may be copied in full, with copyright, contact, creation and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Mercola is required.

Terms & Conditions • Updated Privacy Policy
© 1997-2022 Dr. Joseph Mercola. All Rights Reserved.

TrustedSite CERTIFIED SECURE

TRUSTe Certified Privacy Powered by TrustArc